Ignite Creation Date:
2024-05-06 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03529110
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-12
First Post:
2018-04-13
Brief Title:
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 HER2-Positive Unresectable andor Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane DESTINY-Breast03
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-08-09
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2018-04-13
First Submit QC Date:
May 7 2018
Study First Post Date:
2018-05-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-04-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-29
Last Update Post Date:
2024-06-12
Last Update Post Date Type:
ACTUAL